Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Bank of America Analyst Says

Johnson & Johnson (NYSE:JNJ) had its target price boosted by investment analysts at Bank of America from $253.00 to $254.00 in a research note issued on Wednesday,MarketScreener reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price objective indicates a potential upside of 8.28% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday. Rothschild & Co Redburn upped their target price on Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a report on Thursday, February 19th. TD Cowen assumed coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 target price for the company. Barclays lifted their price target on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $251.52.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $234.57 on Wednesday. The firm has a market capitalization of $564.99 billion, a price-to-earnings ratio of 27.12, a PEG ratio of 2.38 and a beta of 0.34. The stock has a fifty day moving average of $241.60 and a 200 day moving average of $216.66. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.75%. The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the firm earned $2.77 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds have recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. United Bank lifted its position in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after purchasing an additional 692 shares during the last quarter. Wealth Group Ltd. increased its holdings in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after purchasing an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. raised its stake in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock worth $11,255,000 after purchasing an additional 6,584 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and raised 2026 outlook — J&J reported stronger-than-expected Q1 results with roughly 10% revenue growth and raised full-year guidance, a core reason bulls point to for further upside. Johnson & Johnson Raises 2026 Outlook As Sales Jump Nearly 10%
• Positive Sentiment: Analysts turn more bullish / lift price targets — Multiple firms have raised price targets or reiterated buy ratings (Goldman Sachs, Morgan Stanley, Argus, Wells Fargo, Raymond James and others), supporting near-term upside expectations. Goldman Sachs Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
• Positive Sentiment: Dividend and income appeal — Coverage pieces highlight J&J’s Dividend King status and growing momentum after its streamlining, keeping it attractive to income and total-return investors. This “Boring” Dividend King Is Quietly Turning Into a Growth Machine
• Neutral Sentiment: Asset sale: MeiraGTx acquires bota‑vec from J&J — J&J has divested interests in a gene‑therapy asset to MeiraGTx; this trims pipeline exposure but can free resources—mixed near-term impact. MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec
• Neutral Sentiment: Investor access / upcoming events — J&J will present at the Bank of America Healthcare Conference (May 12), a potential catalyst for new forward guidance or clarity on execution. Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
• Negative Sentiment: Biosimilar / Stelara headwinds and rising costs — Management flagged ongoing pressure from biosimilar competition (notably affecting Stelara) and some cost/inflation headwinds, which temper margin and growth visibility. J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.